On February 8, 2023 Tailor Bio, an innovative techbio company, reported that it has secured £2 million in funding to advance its pan-cancer precision medicine platform (Press release, Tailor Bio, FEB 8, 2023, View Source [SID1234641527]). The funding round was led by London-based Ascension Life Fund, with support from Time-Boost Capital, Acequia Capital, First-In Ventures, Illumina Accelerator, Cambridgeshire & Peterborough Combined Authority and prominent genomics angel investor Graham Snudden (Founder of BlueGnome, acquired by Illumina).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Tailor Bio’s platform aims to make precision medicine a reality for the deadliest cancers by providing new insight into chromosomal instability (CIN). CIN is a genomic phenomenon present in 80% of all cancers and extreme CIN is typically found in more aggressive, difficult to treat cancers1. Tailor Bio’s platform provides unique understanding of CIN to help identify new therapeutic targets and improve patient stratification for more targeted and effective treatments.
Tailor was founded to translate cutting edge cancer research from academia to patient benefit. The company’s scientific co-founders include group leaders Dr Geoff Macintyre from the Spanish National Cancer Institute, Professor James Brenton, Professor Florian Markowetz and Dr Anna Piskorz from Cancer Research UK Cambridge Institute, University of Cambridge.
The company is also proud to announce that Professor Steve Jackson has joined the team as an advisor. Professor Jackson is a renowned cancer researcher and was instrumental in the development of the PARP inhibitor olaparib, which is currently used to treat certain types of ovarian, breast, prostate and pancreatic cancers. He has also founded several successful biotech startups, which together with his expertise in cancer research and drug development will be invaluable as Tailor Bio continues to develop its platform.
Tailor Bio CEO, Jason Yip, said: "We are thrilled to have secured this funding, which will enable us to further develop and deploy our platform in order to provide new and more effective treatments for cancer patients by using precision medicine. We are excited to accelerate our work with the guidance of Professor Steve Jackson and the support of our investors."
Dr. Ala Alenazi, Principal at Ascension Life Fund said: "The healthcare impact, scientific validation and team vision won our early conviction in Tailor Bio. The team published a ground-breaking study on the cover of Nature showing that CIN tumours display signatures that can inform a personalised therapeutic approach. The momentum has not stopped since and we’re excited to join them on their journey to supercharge their platform and strategy. We’re also lucky to be joined by a syndicate of brilliant investors and angels."
The funds will be used to further develop the platform, grow the team and expand the company’s operations.
For further information please contact [email protected].